STAB News and Press, Statera Biopharma Inc.

2025-02-12 10:40:00 ET Today was a big day for one small cap biotech company. The company announced that they had acquired worldwide exclusive license rights to a late-stage Toll-like Receptor 5 (TLR5) agonist for the treatment of acute radiation syndrome. The news sparked strong in...

2025-02-12 09:34:07 ET DENVER, Colo., Feb 12, 2025 ( 247marketnews.com )- Tivic Health Systems (NASDAQ: TIVC ) announced the acquisition of worldwide exclusive license rights from Statera Biopharma (OTC: STAB ) for Entolimod, a Toll-like Receptor 5 (TLR5) agonist that is in late...